<?xml version="1.0" encoding="UTF-8"?>
<p>Despite the clear interests of pregnant women in accessing new drugs and vaccines for Covid‐19, these individuals are not actively being recruited to participate in Covid‐19 vaccine and treatment trials. For instance, the drug hydroxychloroquine was one of the first pharmaceutical agents under investigation for the treatment of Covid‐19, yet the initial published trial data does not include data from pregnant trial participants,
 <xref rid="eahr500060-bib-0011" ref-type="ref">
  <sup>11</sup>
 </xref> even though its use in pregnant women with preexisting autoimmune disease has already been studied. From the available observational studies, the drug is known to cross the placenta and be found in breast milk,
 <xref rid="eahr500060-bib-0012" ref-type="ref">
  <sup>12</sup>
 </xref> but it does not appear to be associated with an increased risk of fetal or maternal complications. Initial studies have not concluded that hydroxychloroquine is an effective treatment for SARS‐CoV‐2, and, thus, the search for an effective agent must continue. Yet the ways in which these initial studies were conducted raise important questions about attitudes and policies regarding the inclusion of pregnant women in trials during the Covid‐19 pandemic.
</p>
